Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression

Clinical trial NCT06560528 · RECRUITING

Trial details

NCT number

NCT06560528

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Status

RECRUITING

Phase

Phase 2

Study type

INTERVENTIONAL

Start date

2024-09-01

Primary completion

2027-09-01

Enrollment

40

View on ClinicalTrials.gov